Research programme: antibacterials - Sun Pharmaceutical Industries

Drug Profile

Research programme: antibacterials - Sun Pharmaceutical Industries

Alternative Names: RBx 1000075; RBx 1000276; RBx 6247; RBx 8700

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ranbaxy Laboratories
  • Class Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gram-positive infections; Respiratory tract infections; Tuberculosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in India
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-infections in India
  • 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top